Weight management program can put Type 2 diabetes into remission finds Lancet study

0663742d-a49d-4c62-8550-1233d5ff7522articleimage.jpg

06 Dec 2017 --- Type 2 diabetes can be reversed following an intensive weight management program, according to a randomized trial in adults who have had the condition for up to six years, published in The Lancet. The findings lend support to the widespread use of this type of intervention in the routine care of Type 2 diabetes across health services.

The positive results of the study show that after a year, participants had lost an average of 10kg, and nearly half had reverted to a non-diabetic state without using any diabetes treatment.

“Our findings suggest that even if you have had Type 2 diabetes for six years, putting the disease into remission is feasible,” says Professor Michael Lean from the University of Glasgow, who co-led the study. “In contrast to other approaches, we focus on the need for long-term maintenance of weight loss through diet and exercise and encourage flexibility to optimize individual results.”

Addressing root cause
Worldwide, the number of people with Type 2 diabetes has quadrupled over 35 years, rising from 108 million in 1980 to 422 million in 2014. This is expected to climb to 642 million by 2040. This increase has been linked to rising levels of obesity and the accumulation of intra-abdominal fat.

“Rather than addressing the root cause, management guidelines for Type 2 diabetes focus on reducing blood sugar levels through drug treatments. Diet and lifestyle are touched upon but diabetes remission by cutting calories is rarely discussed,” explains Professor Roy Taylor from Newcastle University, UK, who co-led the study.

“A major difference from other studies is that we advised a period of dietary weight loss with no increase in physical activity, but during the long-term follow up, increased daily activity is important,” Professor Taylor adds.

Previous research by the same team confirmed the Twin Cycle Hypothesis-that Type 2 diabetes is caused by excess fat within the liver and pancreas and established that people with the disease can be returned to normal glucose control by consuming a very low-calorie diet. But whether this type of intensive weight management was practicable and could achieve remission of Type 2 diabetes in routine primary care was not known until now.

The Diabetes Remission Clinical Trial (DiRECT) included 298 adults aged 20 to 65 years who had been diagnosed with Type 2 diabetes in the past six years from 49 primary care practices across Scotland and the Tyneside region of England between July 2014 and August 2016. Practices were randomly assigned to provide either the Counterweight-plus weight management program delivered by practice dieticians or nurses (149 individuals) or best practice care under current guidelines (control; 149 individuals).

The weight management program began with a diet replacement phase, consisting of a low calorie formula diet (825 to 853 calories per day for three to five months), followed by stepped food reintroduction (two to eight weeks), and ongoing support for weight loss maintenance including cognitive behavioral therapy combined with strategies to increase physical activity. Anti-diabetic and blood pressure-lowering drugs were all stopped at the start of the program.

The primary outcomes were weight loss of 15kg or more (sufficient to achieve remission of diabetes in most cases) and remission of diabetes. Remission was defined as achievement of a glycated hemoglobin A1c (HbA1c) level of less than 6.5 percent at 12 months, off all medications.

Almost a quarter (36 of 149) of the weight management group achieved weight loss of 15kg or more at 12 months, compared with none in the control group. Additionally, nearly half of the weight management group (68 of 149) achieved diabetes remission at one year, compared with six (4 percent) in the control group.

On average, participants in the weight management group shed 10kg of bodyweight compared to 1kg in the control group. Importantly, the results showed that remission was closely linked with the degree of weight loss and occurred in around nine out of ten people who lost 15kg or more, and nearly three quarters (47 of 64) of those who lost 10kg or more.

However, the authors note that the vast majority of participants were white and British, meaning that the findings may not apply to other ethnic and racial groups such as south Asians, who tend to develop diabetes with less weight gain.

Make achievable weight loss primary goal
“Our findings suggest that the very large weight losses targeted by bariatric surgery are not essential to reverse the underlying processes which cause Type 2 diabetes,” says Professor Taylor. “The weight loss goals provided by this program are achievable for many people. The big challenge is long-term avoidance of weight re-gain. Follow-up of DiRECT will continue for four years and reveal whether weight loss and remission is achievable in the long-term.”

Writing in a linked Comment, Professor Emeritus Matti Uusitupa from the University of Eastern Finland discusses whether these findings should change treatment options for Type 2 diabetes: “Lean and colleagues’ results, in addition to those from other studies of Type 2 diabetes prevention and some smaller interventions in this setting, indicate that weight loss should be the primary goal in the treatment of Type 2 diabetes.”

“The DiRECT study indicates that the time of diabetes diagnosis is the best point to start weight reduction and lifestyle changes because motivation of a patient is usually high and can be enhanced by the professional health-care providers,” Prof. Uusitupa adds. “However, disease prevention should be maintained as the primary goal that requires both individual-level and population-based strategies, including taxation of unhealthy food items to tackle the epidemic of obesity and Type 2 diabetes.”

Related Articles

Nutrition & Health News

Researchers create app to predict and intervene in users' overeating

13 Dec 2017 --- Researchers at Worcester Polytechnic Institute (WPI) and the University of Connecticut (UConn) are collaborating on a smartphone app aimed at helping users manage their overeating challenges in three key ways: by tracking eating patterns, providing interventions and helping change behavior. According to the researchers, the app and its distinctive methodology have shown “tremendous promise” in an early pilot study.

Nutrition & Health News

Relief from food allergies may come from antibody drug and food desensitization

12 Dec 2017 --- A clinical trial of 48 children with multiple food allergies which tested antibody drug omalizumab alongside food desensitization treatment resulted in more effective allergy relief compared to placebo, according to a study published in The Lancet Gastroenterology & Hepatology journal.

Business News

Inflammatory bowel disease rates on the rise outside West, says new study

08 Dec 2017 --- Countries in Africa, Asia, the Middle East and South America have seen a rise in incidence of inflammatory bowel disease as they have become increasingly industrialized and Westernized, a new study has found. The research – a collaboration between the University of Birmingham, UK, the University of Calgary, Canada, and the Chinese University of Hong Kong – is described by the University of Birmingham as the most definitive and comprehensive study of the global epidemiology of inflammatory bowel disease.

Business News

Consuming sugary drinks during pregnancy may increase asthma risk in mid-childhood

08 Dec 2017 --- Children between the ages of 7 and 9 may be at greater risk for developing asthma if they consumed high amounts of fructose in early childhood or their mothers drank a lot of sugar-sweetened beverages while pregnant, according to new research published online in the Annals of the American Thoracic Society.

Business News

Nestle acquires Atrium for US$2.3 billion, extends consumer healthcare portfolio

06 Dec 2017 --- Nestle has agreed to acquire Canadian nutritional health products manufacturer Atrium Innovations from a group of investors led by Permira Funds for US$2.3 billion in cash. Nestle notes that the move for the company, whose 2017 sales are expected to reach almost US$700 million, supports Nestle’s pursuit of growth opportunities in consumer healthcare to complement the company's focus on its high-growth food and beverage categories.

More Articles
URL : http://www.nutritioninsight.com:80/news/weight-management-program-can-put-type-2-diabetes-into-remission-finds-lancet-study.html